[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@MattyKirsh Matthew Kirshner

Matthew Kirshner posts on X about $crvo the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Month XXXXXX +50%
• X Months XXXXXX -XX%
• X Year XXXXXXX +38%

Mentions: X #

• X Month X +17%
• X Months XX -XX%
• X Year XX +76%

Followers: XXXXX #

• X Week XXXXX +1.80%
• X Month XXXXX +7%
• X Months XXXXX +15%
• X Year XXXXX +54%

CreatorRank: undefined #

Social Influence #

---

Social topic influence $crvo

Top Social Posts #

---

Top posts by engagements in the last XX hours

"I've followed $CRVO for some time but only recently appreciated how distinct its data are for Dementia with Lewy Bodies (DLB). I had assumed (similar to Alzheimers) that loads of prior DLB drugs have come before that have shown Phase X benefit only to fail in Phase X. In fact no prior DLB drug has ever demonstrated a stat-sig placebo-controlled improvement on a cognitive endpoint (excluding slight symptomatic relief from cholinesterase inhibitors). $CRVO's neflamapimod appears to be the first. In reviewing every Phase 2+ DLB trial I could find no other drug achieved significance on a"
X Link @MattyKirsh 2025-10-14T12:20Z 1833 followers, XXX engagements